Get started
JAMJOOM PHARMACEUTICALS FACTORY CO.JAMJOOM PHARMACEUTICALS FACTORY CO.JAMJOOM PHARMACEUTICALS FACTORY CO.

JAMJOOM PHARMACEUTICALS FACTORY CO.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

4015 chart


Full chart

4015 upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪10.92 B‬ SAR
Dividend yield (indicated)
1.96%
Price to earnings Ratio (TTM)
30.6
Basic EPS (TTM)
5.0 SAR
Net income (FY)
‪356.52 M‬ SAR
Revenue (FY)
‪1.32 B‬ SAR
Shares float
‪21.00 M‬
Beta (1Y)
0.62

Employees


Employees (FY)
‪1.08 K‬
Revenue / Employee (1Y)
‪1.22 M‬ SAR
Net income / Employee (1Y)
‪330.42 K‬ SAR

About JAMJOOM PHARMACEUTICALS FACTORY CO.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Tarek Youssef Hosni
Website
jamjoompharma.com
Headquarters
Jeddah
Founded
1994
ISIN
SA15QGU1UNH6
FIGI
BBG01C5P2446
Jamjoom Pharmaceuticals Factory Co. engages in the development, manufacturing, and marketing of generic pharmaceutical products. It operates through Pharmaceutical Products and Consumer Health Products segments. The Pharmaceutical Products segment represents medicines or drugs that are essential for the prevention and treatment of diseases, and protection of public health. The Consumer Health Products segment covers products that does not require the oversight of a health care practitioner. The firm's products are primarily sold in Saudi Arabia, Egypt, Iraq, Gulf countries, and North Africa countries. The company was founded by Yousuf Mohammed Salah Abdulaziz Jamjoom on September 22, 1994 and is headquartered in Jeddah, Saudi Arabia.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

4015 news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as 4015.

Frequently Asked Questions


The current price of 4015 is 150.4 SAR — it has decreased by −3.59% in the past 24 hours. Watch JAMJOOM PHARMACEUTICALS FACTORY CO. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TADAWUL exchange JAMJOOM PHARMACEUTICALS FACTORY CO. stocks are traded under the ticker 4015.
4015 stock has fallen by −3.59% compared to the previous week, the month change is a −10.48% fall, over the last year JAMJOOM PHARMACEUTICALS FACTORY CO. has showed a 16.05% increase.
We've gathered analysts' opinions on JAMJOOM PHARMACEUTICALS FACTORY CO. future price: according to them, 4015 price has a max estimate of 187.00 SAR and a min estimate of 165.30 SAR. Watch 4015 chart and read a more detailed JAMJOOM PHARMACEUTICALS FACTORY CO. stock forecast: see what analysts think of JAMJOOM PHARMACEUTICALS FACTORY CO. and suggest that you do with its stocks.
4015 reached its all-time high on Sep 19, 2024 with the price of 202.4 SAR, and its all-time low was 66.0 SAR and was reached on Jun 20, 2023. View more price dynamics on 4015 chart.
See other stocks reaching their highest and lowest prices.
4015 stock is 4.13% volatile and has beta coefficient of 0.62. Track JAMJOOM PHARMACEUTICALS FACTORY CO. stock price on the chart and check out the list of the most volatile stocks — is JAMJOOM PHARMACEUTICALS FACTORY CO. there?
Yes, you can track JAMJOOM PHARMACEUTICALS FACTORY CO. financials in yearly and quarterly reports right on TradingView.
JAMJOOM PHARMACEUTICALS FACTORY CO. is going to release the next earnings report on Jun 30, 2025. Keep track of upcoming events with our Earnings Calendar.
4015 net income for the last quarter is ‪51.61 M‬ SAR, while the quarter before that showed ‪94.99 M‬ SAR of net income which accounts for −45.67% change. Track more JAMJOOM PHARMACEUTICALS FACTORY CO. financial stats to get the full picture.
JAMJOOM PHARMACEUTICALS FACTORY CO. dividend yield was 2.01% in 2024, and payout ratio reached 60.08%. The year before the numbers were 2.19% and 59.85% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Apr 4, 2025, the company has ‪1.08 K‬ employees. See our rating of the largest employees — is JAMJOOM PHARMACEUTICALS FACTORY CO. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. JAMJOOM PHARMACEUTICALS FACTORY CO. EBITDA is ‪418.12 M‬ SAR, and current EBITDA margin is 31.70%. See more stats in JAMJOOM PHARMACEUTICALS FACTORY CO. financial statements.
Like other stocks, 4015 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade JAMJOOM PHARMACEUTICALS FACTORY CO. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So JAMJOOM PHARMACEUTICALS FACTORY CO. technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating JAMJOOM PHARMACEUTICALS FACTORY CO. stock shows the neutral signal. See more of JAMJOOM PHARMACEUTICALS FACTORY CO. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.